Tier 4 — mechanistic

Fisetin Intervention Study in Mild Alzheimer's Disease

Sunnybrook Health Sciences Centre study team
ClinicalTrials.gov trial registry record 2025

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Sunnybrook Health Sciences Centre.
Competing interests
Not reported in the registry record.

Study snapshot

DesignPhase 2 pilot interventional study focused on safety and tolerability.
ModelOlder adults with mild cognitive impairment or mild Alzheimer's disease dementia.
SampleActual enrollment: 5 participants.
InterventionFisetin approximately 20 mg/kg/day; the public summary does not provide enough detail to define the full dosing schedule confidently.
DurationPrimary safety/tolerability outcome assessed over approximately 30 days; study completed July 2026.
EndpointsSafety and tolerability; Exploratory cognitive and biomarker measures

What the study showed, in plain terms

This Canadian pilot directly tested fisetin in five people with mild cognitive impairment or mild Alzheimer's disease. The study completed in July 2026 and was designed primarily to assess safety and tolerability.

No outcome results were available in the public sources reviewed, so the completed status should not be mistaken for evidence that fisetin improves cognition or Alzheimer's disease.

Key findings

  • The trial completed with five participants.
  • The registered intervention used approximately 20 mg/kg/day of fisetin.
  • The study was an early safety/tolerability pilot rather than a powered efficacy trial.

What this study can and cannot tell us

  • Extremely small sample size.
  • No posted results were available at verification.
  • No inference about cognitive efficacy can be made from a completed registry entry alone.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology